2008–2009 Scholarship Applications Now Available
Wyeth continues its commitment to providing education and assistance to people with hemophilia and their families through the Soozie Courter "Sharing a Brighter Tomorrow" Hemophilia Scholarship Program.

For the 2008–2009 academic year, Wyeth will award up to $100,000 in scholarships to students in the hemophilia community, including

• Two $7,500 graduate scholarships
• Sixteen $5,000 college scholarships
• Two $2,500 vocational scholarships

To be eligible for the scholarships, students must have either hemophilia A or hemophilia B and be a high school senior, have a graduate equivalency diploma (GED), or be currently enrolled in an accredited junior college, college (undergraduate or graduate), or vocational school.

To download and print a scholarship application form for the 2008–2009 academic year, click here. Applications are also available at your treatment center or by calling the Wyeth Hemophilia Hotline at 1-888-999-2349. Completed applications must be postmarked no later than April 4, 2008.

In 2000, the program was renamed the Soozie Courter "Sharing a Brighter Tomorrow" Hemophilia Scholarship Program to recognize Soozie Courter, a valued and respected friend of the hemophilia community who passed away in 1999.

To view a list of 2007–2008 scholarship winners, click here.

To view a list of 2006–2007 scholarship winners, click here.

Indication
BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings. BeneFIX is not indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X) nor the treatment of hemophilia A patients with inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation, nor the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Important Safety Information

	•	As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or tiredness.
	•	BeneFIX may be contraindicated in patients with a known history of hypersensitivity to hamster protein.
	•	Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur.

Please see BeneFIX Prescribing Information

Indication
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

Important Safety Information

	•	As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions.
	•	The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.
	•	Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see ReFacto Prescribing Information